MIT-founded regenerative polymer developer Tissium will put the capital into clinical-stage development and toward regulatory clearance in multiple markets.
Tissium, a France-based developer of regenerative synthetic polymers spun out of Massachusetts Institute of Technology (MIT), closed a €38.8m ($42.8m) series B round featuring government-owned investment bank Bpifrance yesterday.
BNP Paribas Développement, an investment subsidiary of financial services firm BNP Paribas, also took part in the round together with the EU-owned European Investment Fund, M&L Investments, Valquest Partners, CM-CIC Innovation, CapDecisif Management, Omnes Capital and Sofinnova Partners.
Founded in 2013 as Gecko Biomedical, Tissium has devised a synthetic…
